Featured

Case Studies of Patients with Diabetic Foot Ulcers Showed 90 to 100 Percent Wound Closure at 12 weeks Following Weekly Treatment with Novel OMEZA® OCM™

–Three case studies reinforce clinical trial data demonstrating dramatic healing rates among patients with diabetic foot ulcers treated with OCM™ – CLEVELAND – June 11, 2024 – Omeza®, a regenerative skincare company …

OMEZA® CLINICAL STUDY TO EVALUATE OCM™ WOUND MATRIX FOR THE TREATMENT OF CHRONIC CUTANEOUS WOUNDS/ULCERS OF MULTIPLE ETIOLOGIES HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS WILL BE SUBMITTED TO A PEER REVIEW JOURNAL.

Sarasota, FL June 6, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center clinical study which evaluated …

NOVEL OMEZA® OCM™ WOUND MATRIX CLINICAL STUDY IN VENOUS LEG ULCERS HAS COMPLETED ENROLLMENT AND FINAL DATABASE LOCK. FULL RESULTS TO BE SUBMITTED TO PEER REVIEW JOURNAL

Sarasota, FL June 5, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced completion of a multi-center open label study comparing …

POSITIVE DATA FROM IN VIVO STUDY SHOWS SIGNIFICANT ANTIMICROBIAL ACTIVITY OF OCM™ AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PSEUDOMONAS AERUGINOSA (PA) IN PORCINE WOUND MODEL

Sarasota, Fla, May 20, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing that OCM™ wound matrix alone …

NOVEL OMEZA® OCM™ WOUND MATRIX DEMONSTRATES MULTIMODAL EFFECTS BY REDUCING BACTERIAL CONTAMINATION IN “STALLED”, HARD TO TREAT WOUNDS, WHILE SUPPORTING HEALING RATES

SARASOTA, Fla., May 14, 2024 /PRNewswire/– Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today announced a submission of an evaluation of OCM™ Wound …

NOVEL OMEZA® OCM™ WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS

LONDON, May 3, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical …

Positive Results from Diabetic Foot Ulcer Clinical Trial Show Dramatic Healing Rate within 12 Weeks or Less Using Novel OMEZA® Platform and Offloading

Sarasota, Fla., March 14, 2024 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) …

OCM™ Wound Platform Demonstrates Antibacterial Activity in Porcine Wound Model, Significantly Reducing Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) Compared to Comparator and Control Groups

SARASOTA, Fla., Dec. 8, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCM™ alone significantly reduced …

New Clinical Data Demonstrate >90 Percent Area Reduction in Diabetic Foot Ulcers within 12 Weeks or less Using Novel Omeza® Platform plus Offloading

SARASOTA, Fla., Dec. 6, 2023 — Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced interim clinical trial results showing that Omeza® combination therapy …

Omeza Announces New Tranche of Funding and Upcoming Q3 Clinical Activities

SARASOTA, Fla., Sept. 27, 2023 — Omeza, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today announced that it has completed a $6.5 million offering and …

Our Mission

Omeza Quick Links